Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of BAT3306 vs Keytruda in Healthy Male Subjects
NCT06111196Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pembrolizumab in solid tumor and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Clearance at Day 113, Maximum Observed Plasma Concentration at Day 113 and 5 more. Started Nov 2023; status: completed.
02
Drugs
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06111196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111196.